BVM Capital LLC is a Southeast-based venture capital firm that seeks to create and finance breakthrough early and expansion stage companies with proprietary technology platforms or unique products which will lead to the treatment and ultimate cure for cancers. 

TransBio Ventures, LLC, launched by BVM in 2016, is a life science and oncology fund investing in companies affiliated with MD Anderson Cancer Center.   More information about Transbio Ventures can be found here.

Recent Posts

Houston Biotech Esperance Eyes $40M Raise to Fund Cancer Drug Push

Xconomy Texas — March 30, 2016 Houston — Brett Giroir, the former head of Texas A&M University’s Health Science Center, has a new biotech venture in Houston, and has brought along innovation from his home state of Louisiana. Giroir has joined the board of Esperance Pharmaceuticals, a biotech developing drugs for a variety of cancers. Esperance was founded … Continue reading Houston Biotech Esperance Eyes $40M Raise to Fund Cancer Drug Push

Esperance Pharmaceuticals Names Brett Giroir MD to Board of Directors

Brings Unique Expertise and Perspective from Leadership Positions at Distinguished Academic, Government and Entrepreneurial Healthcare Institutions Company Opens Offices in Houston as EP-100 Advances in Ovarian and Breast Cancer Trials Conducted in Collaboration with MD Anderson Cancer Center Mar 17, 2016, 07:30 ET from Esperance Pharmaceuticals, Inc. HOUSTON, March 17, 2016 /PRNewswire/ — Esperance Pharmaceuticals Inc. … Continue reading Esperance Pharmaceuticals Names Brett Giroir MD to Board of Directors

Baton Rouge cancer drug developer partners with MD Anderson

BY TED GRIGGS tgriggs@theadvocate.com AUG 29, 2015 – 5:04 PM A Baton Rouge cancer treatment startup has drawn the attention of MD Anderson Cancer Center and a deal to accelerate development of the company’s lead anti-cancer drug. Under the agreement with Esperance Pharmaceuticals Inc., Houston-based MD Anderson will conduct additional studies to help prepare for … Continue reading Baton Rouge cancer drug developer partners with MD Anderson

Esperance Announces Strategic Alliance with MD Anderson Cancer Center

Esperance and MD Anderson Will Collaborate to Accelerate Development of EP-100 in Ovarian and Breast Cancer Aug 24, 2015, 07:30 ET from Esperance Pharmaceuticals, Inc. BATON ROUGE, La., Aug. 24, 2015 /PRNewswire/ — Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead … Continue reading Esperance Announces Strategic Alliance with MD Anderson Cancer Center

More Posts